261 related articles for article (PubMed ID: 22460117)
1. Rare diseases and orphan drugs.
Melnikova I
Nat Rev Drug Discov; 2012 Mar; 11(4):267-8. PubMed ID: 22460117
[No Abstract] [Full Text] [Related]
2. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
Bashaw ED
Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
[TBL] [Abstract][Full Text] [Related]
3. Drug labels: a flawed source of data for studying orphan drug approvals.
Kesselheim AS; Avorn J
Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
[No Abstract] [Full Text] [Related]
4. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
5. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
6. A human-on-a-chip approach to tackling rare diseases.
de Mello CPP; Rumsey J; Slaughter V; Hickman JJ
Drug Discov Today; 2019 Nov; 24(11):2139-2151. PubMed ID: 31412288
[TBL] [Abstract][Full Text] [Related]
7. Accelerating orphan drug development.
Coté TR; Xu K; Pariser AR
Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
[TBL] [Abstract][Full Text] [Related]
8. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
9. Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases.
Rudek MA; Korth-Bradley JM
Clin Pharmacol Ther; 2016 Oct; 100(4):333-5. PubMed ID: 27393720
[TBL] [Abstract][Full Text] [Related]
10. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
[TBL] [Abstract][Full Text] [Related]
11. Challenges and Opportunities in Rare Disease Drug Development.
Smith BP
Clin Pharmacol Ther; 2016 Oct; 100(4):312-4. PubMed ID: 27612019
[TBL] [Abstract][Full Text] [Related]
12. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
13. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
14. Rare-disease drugs to receive consideration on par with serious-disease drugs.
Thompson CA
Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
[No Abstract] [Full Text] [Related]
15. Orphan drug development in China: progress and challenges.
Zhang S; Chen L; Zhang Z; Zhao Y
Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
[No Abstract] [Full Text] [Related]
16. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
17. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
18. Ethical considerations in orphan drug approval and use.
Kesselheim AS
Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
[TBL] [Abstract][Full Text] [Related]
19. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
20. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
